Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: PTEN Hamartoma Syndrome Clear all

Conditions: Cowden's Disease, Hamartoma Syndrome, Multiple
Interventions: fludeoxyglucose F 18, sirolimus, Clinical Videography; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: PTEN, ASD, Autism, Macrocephaly, PTEN Hamartoma Tumor Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome, Cowden Syndrome, Bannayan Syndrome, Bannayan Zonana Syndrome, Polyposis
Interventions: Sirolimus; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions: BGT226; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas

Conditions: Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions: Everolimus blinded oral capsules, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Breast Cancer Surgery
Interventions: Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy; Procedure
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 4,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more

Conditions: PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Interventions: RAD001, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Palo Alto, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Breast Cancer, Advanced Solid Tumors, Cowden Syndrome
Interventions: BEZ235; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 6 more

Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PTEN Gene Mutation
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: PTEN Hamartoma Tumor Syndrome
Interventions: NET; Diagnostic Test
Lead sponsor: John Carroll University; Other
Eligibility: 3 Years to 45 Years
Enrollment: 300 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: University Heights, Ohio

Search by objective public record fields.

Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

Familial Investigations of Childhood Cancer Predisposition

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

Sirolimus for Cowden Syndrome With Colon Polyposis

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome

Development and Validation of an Online Neurobehavioral Evaluation Tool for PTEN Patients